Hohe Lipoprotein(a)-Werte als schwerwiegender Risikofaktor für die koronare Herzkrankheit – Darstellung von 6 Kasuistiken

Zusammenfassung

Erhöhte Lipoprotein(a)-Spiegel sind ein isolierter und schwerwiegender Risikofaktor für eine Arterioskleroseentwicklung, was noch nicht ausreichend bekannt ist. Bei allen Patienten mit frühzeitig auftretenden und/oder rezidivierenden Gefäßkomplikationen sowie bei ungünstiger Familienanamnese bezüglich kardiovaskulärer Erkrankungen ist die Messung von Lipoprotein(a) notwendig.

Wir haben am Beispiel von 6 Kasuistiken bei zum Teil noch sehr jungen Patienten die Beziehung zwischen erhöhten Lipoprotein(a)-Spiegeln und schweren kardiovaskulären Komplikationen dargestellt und dabei auch weitere Risikofaktoren diskutiert.

Ziel ist es, die Bedeutung erhöhter Lipoprotein(a)-Spiegel Hausärzten, Kardiologen, Angiologen, Diabetologen und Nephrologen zu verdeutlichen, damit die betroffenen Patienten rasch einer effektiven Therapie zugeführt werden können.

Abstract

Elevated Lipoprotein(a) levels represent an isolated and severe risk factor inducing atherosclerosis; this fact is not yet sufficiently known. In all patients with an early manifestation and / or recurring vascular complications as well as an unfavorable family history with respect to cardiovascular diseases the measurement of Lipoprotein(a) is needed.

Based on the example of 6 cases who were in part still very young we describe the relationship between elevated Lipoprotein(a) levels and severe cardiovascular complications and also discuss further risk factors.

The aim of this paper is to emphasize the significance of increased Lipoprotein(a) concentrations which should be taken into account by family doctors, cardiologists, angiologists, diabetologists, and nephrologists, so that the affected patients could rapidly undergo an effective therapy.

Schlüsselwörter

erhöhtes Lipoprotein(a) - Hypercholesterinämie - Gefäßkomplikationen - Familienanamnese

Key words

elevated lipoprotein(a) - hypercholesterolemia - cardiovascular complications - family history

• Literatur

• 1 Safarova MS, Ezhoy MV, Afanasieva OI et al. Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis. J Clin Apher 2015; 30: 193-195
• 2 Jaeger BR, Richter Y, Nagel D. Group of Clinical Investigators et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 229-239
• 3 Leebmann J, Roeseler E, Julius U. Pro(a) LiFe Study Group et al. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128: 2567-2576
• 4 Rosada A, Kassner U, Vogt A et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?. Artificial Organs 2014; 38: 135-141
• 5 von Dryander M, Fischer S, Passauer J et al. Differences in the atherogenic risk of patients, treated by lipoprotein apheresis according to their lipid pattern. Atherosclerosis Suppl 2013; 14: 39-44
• 6 Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
• 7 Cannon CP, Blazing MA, Giuglian RP et al. for the IMPROVE – IT Investigators Ezetimibe added to statin therapy after acute coronary syndrome. N Engl J Med 2015; 372: 2387-2397
• 8 Sandkamp M, Funke H, Schulte HG et al. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20-23
• 9 Bergmann S, Sandkamp M, Assmann G. and DRECAN-Team et al. Lp(a)-Verteilung in der Dresdner Bevölkerung (DRECAN-Studie). Blaubeuren Jahrfestagung; 1992 Ref Type: Generic
• 10 Kostner GM, Avogaro P, Cazzolato G et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61
• 11 Lamon-Fava S, Marcovina SM, Albers JJ et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011; 52: 1181-1187
• 12 Schettler VJJ, Roeseler E, Thode C et al. Differenzierung der Indikation zur Lipoproteinapherese bei erhöhtem Lp(a) durch unterschiedliche Messmethoden. Cardiovasc 2015; 15 (03) 36-38
• 13 Marcovina SM, Albers JJ. Lp(a) Measurements for Clinical Application. J Lipid Res 2015; , Dec 4 jlr R 061648 Epub ahead of print
• 14 Dati F, Tate JR, Marcovina SM et al. First HWHO7IFCC International reference Reagent for Lipoprotein(a) for Immunoassay-Lp(a) SRM2B. Clin Chem Lab Med 2004; 42: 670-676
• 15 Tselmin S, Mueller G, Gelgaft E et al. An elevated lipoprotein(a) plasma level as a cardiovascular risk factor. Atherosclerosis Supplements 2015; 18: 257-262